Skip to main content
. 2021 Feb 22;13(4):911. doi: 10.3390/cancers13040911

Figure 4.

Figure 4

Immune responses. IFN-γ ELISpot reactions against IO103, background subtracted. (a) Immune responses in PBMCs per patient. Spots per 2.5 × 105 in patients #1 to #3 and spots per 3.5 × 105 in patients #4 to #10. *: DFRx1, **: DFRx2 (b) Immune responses in PBMCs per timepoint, samples from patient #4 to #10 have been normalized to spots per 2.5 × 105. For comparisons baseline to after two and after six vaccines, repeated measures ANOVA with Tukey’s multiple comparisons test was used, for comparison of baseline to after eight vaccines, paired t test was used, for both tests p ≤ 0.05 considered significant. (c) Immune responses in skin-infiltrating lymphocytes. SKILs from patient #6 did not grow sufficiently. Patient #7 did not have DTH performed. SKILs tested in IFN-γ ELISpot against IO103 or a scrambled control peptide. SKILs per well: Pt #1: 3.0 × 105, Pt #2: 1.0 × 105, Pt #3: 1.2 × 105, Pt #4: 2.85 × 105, Pt #5: 1.7 × 105, Pt #8: 2.0 × 105, Pt #9: 2.25 × 105, Pt #10: 2.6 × 105. *: DFRx1, **: DFRx2. SKILs from patient #2 were tested in duplicate, a Student’s t test p = 0.11. NS = non-significant.